The Importance of Supply Security
The COVID-19 pandemic worldwide has caused immense strain on the pharmaceutical supply chain.
Current realities include:
-
Increased sensitivity over origins of Active Pharmaceutical Ingredients (API)
-
Providing transparency over sourcing of Key Starting Materials (KSM) - origins, gluten/lactose/dye free
-
Heightened transparency over adequate supply of API and safety stock.
-
Shelf-life of product
-
Supply Chain Consistency/readiness
-
Serialization readiness
-
Customers increasing interest in diversifying their supply risk with high volume categories (e.g. women’s health – thyroid) to minimize service disruptions with incumbent suppliers
-
Opportunities for nearshoring - bringing production, manufacturing capabilities closer to home (i.e., US market)
Provell Pharmaceuticals stands ready to meet and exceed these expectations of our customers and patients.
Provell is committed to:
-
Only source products with API/KSM from countries within Europe
-
Maintain at minimum an adequate supply of product to meet existing demand and allocate additional stock to cover for potential supply disruptions (‘levo-insurance’)
-
Utilize high quality standards and control in the manufacturing and distribution of our products throughout the United States.
Provell Pharmaceuticals has committed to full compliance with all Drug Supply Chain Security Act (DSCSA) requirements since 2018.
-
Provell is working with one of the largest serialization, track & trace vendors since 2018.
-
All products are fully serialized for traceability down to the lowest dispensed unit.
Learn how Provell is providing the United States the leading dispensed brand* of levothyroxine worldwide at a generic price to mitigate supply chain risk in these challenging times.
* Source: Data on file – Merck KGaA, Darmstadt, Germany